NCT05238311: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
NCT05238311: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135) Pre-approval Single-patient Expanded Access for...
Dec 1, 2022
294
NCT05271630: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Transplant
NCT05271630: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant Multiple Myeloma Outcomes Based...
Dec 1, 2022
134
NCT05257083: Phase 3: EMN 28 - DVRd -> Cilta-Cel (CART) Vs DVRd -> Transplant ASCT- NDMM CARTITUDE-6
EMN 28 European Myeloma Network EMN28/68284528MMY3005 NCT05257083: Phase 3 : A Study of Daratumumab, Bortezomib, Lenalidomide and...
Dec 1, 2022
2,692
#IMS2022 - 19th International Myeloma Society Annual Meeting; Aug 25-27, LA California
Symplur The #IMS2022 Influencers #IMS2022 - 19th International Myeloma Society Annual Meeting; Aug 25-27, LA California #IMS2022 Myeloma...
Dec 1, 2022
541
NCT05509530: Phase 2: Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating RRMM
NCT05509530: Phase 2: Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple...
Dec 1, 2022
203
Patient Education: Belantamab Mafodotin-blmf (Blenrep) Antibody Drug Conjugate for Multiple Myeloma
Patient Education: Belantamab Mafodotin-blmf * Belantamab mafodotin (Withdrawn from United States market) Belantamab Mafodotin-blmf...
Dec 1, 2022
34
NCT05405166: Phase 3: SC Versus IV Isatuximab in Combination With Pomalidomide & Dexamethasone RRMM
NCT05405166: Phase 3: SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM This is a randomized,...
Dec 1, 2022
272
SCIP & SAVOR FOR A CURE - A Fundraising Hosted By: Fatima and Jimmy Scipione - Sat Oct 15th, 2022
Medfield, Massachusetts - Sat Oct 15th, 2022 From 3 to 8 PM SCIP & SAVOR FOR A CURE - A Fundraising celebration to benefit The...
Dec 1, 2022
79
The Binding Site: Freelite Overview
The Binding Site: Freelite Overview FreeLite Overview Learn more: The Binding Site https://www.youtube.com/c/BindingSite/videos
Dec 1, 2022
123
NCT05455320: Phase 3 - (Talquetamab) Tal-DP Vs Tal-D Vs DPd - RRMM -Multiple Myeloma (MonumenTAL-3)
NCT05455320: Phase 3: A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide...
Dec 1, 2022
400
NCT05199311: Phase 1/2: Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in TE - NDMM
NCT05199311: Phase 1/2: Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma Carfilzomib,...
Dec 1, 2022
172
NCT05308654: Phase 1: A Study to Assess activity & AEs in RRMM Receiving Oral ABBV-453 Tablets
NCT05308654: Phase 1: A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants with Relapsed or...
Dec 1, 2022
779
NCT05519085: Phase 3: CC-92480 + Bortezomib-dex (480Vd) Vs Pom-Bortzomib-dex (PVd) RRMM -SUCCESSOR-1
(SUCCESSOR-1) CC-92480 - Mezi - Mezigdomide - CELMoD NCT05519085: Phase 3: A Study to Evaluate CC-92480, Bortezomib and Dexamethasone...
Dec 1, 2022
207
NCT05427812: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
NCT05427812: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma NCT05427812: Phase 1/2 Study of ISB 1442 in...
Dec 1, 2022
155
Siteman Cancer Center: Autologous stem cell transplant at Siteman Cancer Center
Siteman Cancer Center: Autologous stem cell transplant at Siteman Cancer Center Siteman Cancer Center https://www.youtube.com/user/Sitema...
Dec 1, 2022
114
IMF - International Myeloma Foundation: Patient Handbook 2022
IMF - International Myeloma Foundation: Patient Handbook 2022 Click here to view Patient Handbook Learn more: https://www.myeloma.org/pub...
Dec 1, 2022
361
NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma - iMMagine-1
NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma iMMagine-1 NCT05396885: Phase 2: Study of...
Dec 1, 2022
538
NCT05561387: Phase 3: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma NDMM
SWOG - S2209 - Southwest Oncology Group NCT05561387: Phase 3: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma...
Dec 1, 2022
559
NCT05256446: AMG 701 Expanded Access Program
NCT05256446: AMG 701 Expanded Access Program AMG 701 Expanded Access Program Expanded access requests for AMG 701 may be considered for...
Dec 1, 2022
193